Recommended Free Tools
argenx SE is an antibody-based immunology biotechnology company. Its commercial business is built around efgartigimod medicines in the VYVGART franchise, while its research program develops additional treatments for immune and neuromuscular diseases. The company sells directly in selected markets and works with regional partners elsewhere.
What does argenx do?
argenx discovers, develops and commercializes antibody-based medicines focused on immunology. Its Immunology Innovation Program (IIP) brings together academic researchers, antibody engineers and clinical-development teams to identify and advance drug candidates. The company says candidates in its wholly owned and partnered pipelines have emerged from IIP collaborations. argenx company profile
That model has two connected parts: a marketed-medicine business that generates sales and a research pipeline intended to expand the company’s treatments and indications. The pipeline includes both internal programs and collaborations.
What is VYVGART?
VYVGART is a brand for medicines containing efgartigimod, an engineered fragment of an IgG1 antibody. It targets the neonatal Fc receptor (FcRn), which helps recycle immunoglobulin G (IgG) antibodies. By blocking FcRn-mediated recycling, efgartigimod reduces IgG levels; argenx says it does so without affecting antibody production or other parts of the immune system. argenx 2025 annual report
Free tools Windows power users keep installed
One-click scans. No signup required.
#1 Best Overall
The franchise uses different brand names and formulations in different markets. Approval does not mean every product presentation or indication is available in every country, so patients and investors should check the local regulator’s label.
U.S. adult gMG label expansion
On May 8, 2026, the U.S. Food and Drug Administration approved VYVGART and VYVGART HYTRULO for adults with generalized myasthenia gravis (gMG) across anti-AChR-positive, anti-MuSK-positive, anti-LRP4-positive and triple-seronegative serotypes. This is a U.S. regulatory action; it does not automatically change labels in other countries. argenx announcement of the FDA approval
The annual report’s approval summary, dated February 2026, reported VYVGART approvals in more than 30 countries across three indications and three presentations. It also reported approvals for gMG and chronic inflammatory demyelinating polyneuropathy (CIDP) globally and immune thrombocytopenia (ITP) in Japan under the name VYVDURA. Those figures describe the report’s stated status and are not a substitute for checking current country-specific approvals. argenx 2025 annual report
How does argenx make money?
argenx earns revenue from VYVGART franchise product sales and from collaboration and licensing arrangements. It has its own sales organization for VYVGART in the United States, Japan, Europe and Canada for gMG and CIDP where approved. For Greater China—Mainland China, Hong Kong, Taiwan and Macau—the company’s annual report describes an exclusive efgartigimod development and commercialization license to Zai Lab, with sales-based milestones and royalties tied to annual product net sales. argenx annual report: commercial arrangements argenx annual report: Greater China license
Do these 3 things before closing this tab:
1Fix the driver behind crashes, sound loss and screen glitches2Repair Windows errors before they cause bigger problems3Scan for outdated or missing drivers - takes under a minuteCompany-reported figures show how central the franchise has become, alongside continued investment in research:
| Measure | Company-reported figure | What it indicates |
|---|---|---|
| VYVGART franchise product net sales, 2024 | $2.2 billion | argenx’s reported global product net sales for the year. |
| VYVGART franchise product net sales, 2025 | $4.2 billion | argenx’s reported global product net sales for the year. |
| Research and development investment, 2025 | $1.4 billion | argenx’s reported spending on research and development. |
These are figures reported by argenx, not independent estimates. The company described 2025 as its second year of profitability. argenx annual results
Rank #4
- Murray & Nadel's Textbook of Respiratory Medicine, 2-Volume Set
- Product type: ABIS BOOK
- Brand: Elsevier
What is in argenx’s drug pipeline?
The pipeline includes efforts to extend efgartigimod into more diseases as well as distinct candidates aimed at complement biology and neuromuscular disorders. The programs below are investigational unless a specific local approval is noted; a clinical stage is not evidence that a medicine works or will be approved.
Efgartigimod in additional indications
The 2025 annual report described efgartigimod studies in more than ten additional serious autoimmune indications. In its 2026 outlook, argenx listed studies and expected readouts involving ocular myasthenia gravis, myositis, primary ITP and Sjögren’s disease. These are development plans and expectations, not approved uses or guaranteed outcomes. argenx 2025 annual report argenx 2026 outlook
Best Value
- STRUGGLING WITH PHARMACOLOGY? - Our flashcards simplify studying by breaking down essential drug information into easy-to-digest, bite-sized pieces.
- DESIGNED FOR PHARMACY, NURSING & MEDICAL EXAMS IN 2025 - Created by pharmacy technicians and professional educators to ensure you pass with confidence this year.
- FRONT OF CARDS INCLUDES - Generic name, Rx or OTC, Dosage, Route, Pregnancy category, DEA schedule, and Pronunciation.
- BACK OF CARD INCLUDES - Corresponding brand names, Drug classifications, Common prefixes/suffixes, Mechanism of action, Indications, Contraindications, Side effects, Drug interactions, and Nursing implications.
- ESSENTIAL INFO ONLY - Cards are focused on high-yield information only, reducing information overload and maximizing your exam preparation.
Empasiprubart: complement C2
Empasiprubart is designed to inhibit complement component C2, blocking classical and lectin pathway function while leaving the alternative pathway intact. argenx’s company profile lists two Phase 3 indications for the candidate. argenx pipeline profile
Adimanebart (ARGX-119): neuromuscular junction
Adimanebart is a MuSK agonist program focused on neuromuscular-junction signaling. The company profile lists Phase 3 development for congenital myasthenic syndromes and Phase 2 development for spinal muscular atrophy. argenx pipeline profile
Earlier-stage and partnered programs
- ARGX-213 and ARGX-124: next-generation FcRn candidates. The 2026 outlook anticipated patient trials for ARGX-213 and completion of Phase 1 for ARGX-124 during 2026; those were expectations, not confirmation of completion. argenx pipeline profile argenx 2026 outlook
- ARGX-109: an IL-6-targeting program. argenx pipeline profile
- ARGX-121: an IgA-targeting program. argenx pipeline profile
- TSP-101: a Tensegrity Pharma collaboration program targeting Fn14. argenx pipeline profile
- ARGX-118 and ARGX-125: molecules the company expected to enter Phase 1 in 2026. The expectation should not be treated as evidence that either trial has since begun. argenx 2026 outlook
What is argenx’s Vision 2030?
Vision 2030 is a management ambition, not a forecast or an achieved result. The company’s stated goals are to treat 50,000 patients globally, secure ten labeled indications across approved medicines and advance five pipeline candidates into Phase 3 by 2030. argenx 2026 outlook
Quick Recap
What should investors keep in mind?
- Sales and R&D answer different questions. Franchise sales indicate current commercial scale; research spending reflects investment in future programs, not a guarantee of successful development.
- Pipeline stages are not comparable outcomes. A Phase 3 candidate is further along in clinical development than a Phase 1 candidate, but stage alone does not establish efficacy, safety, regulatory approval or commercial success.
- Geography matters. Product names, presentations, indications and commercial partners can differ by market. A U.S. label or a company-wide approval count cannot establish what is approved for an individual patient in another country.
- Company statements have a perspective. Financial results, pipeline plans and corporate goals here are reported by argenx; they should not be read as independent assessments or investment advice.
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
